![Tim Osborne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Net worth: 321 957 $ as of 2026-06-29
Tim Osborne worked as Principal at the University of California, Irvine.
Mr. Osborne worked as Advisor at Select BioVentures LLC.
Mr. Osborne worked as Senior Vice President-Operations at Forward Air Corp.
from 2013 to 2024.
Mr. Osborne completed undergraduate education at King University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-14 | 23,831 ( 0.08% ) | 321 957 $ | 2026-06-29 |
| Companies | Position | End |
|---|---|---|
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| FORWARD AIR CORPORATION | Chief Operating Officer | - |
Select BioVentures LLC
 Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Private Equity Investor | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
Forward Air Corp.
 Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
 King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Select your edition
All financial news and data tailored to specific country editions
